David Altshuler | |
---|---|
Born |
David Matthew Altshuler Ithaca, NY |
Residence | Brookline, MA |
Alma mater | |
Known for | HapMap |
Spouse(s) | Jill Suttenberg Altshuler |
Awards |
|
Website | www |
Scientific career | |
Institutions | |
Thesis | Endogenous retinal activities that influence the development of rod photoreceptors in vitro (1994) |
Doctoral advisor | Connie Cepko |
David Matthew Altshuler is a clinical endocrinologist and human geneticist. He is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. Prior to joining Vertex in 2014, he was at the Broad Institute of Harvard and MIT., and was a Professor of Genetics and Medicine at Harvard Medical School, and in the Department of Biology at Massachusetts Institute of Technology. He was also a faculty member in the Department of Molecular Biology, Center for Human Genetic Research, and the Diabetes Unit, all at Massachusetts General Hospital. He was one of four Founding Core Members of the Broad Institute, and served as the Institute's Deputy Director, Chief Academic Officer, and Director of the Program in Medical and Population Genetics.
Altshuler attended Commonwealth School in Boston, received his Bachelor of Science from Massachusetts Institute of Technology, his Ph.D from Harvard University, and his M.D. from Harvard Medical School. He completed his internship, residency, and clinical fellowship training at Massachusetts General Hospital.
Altshuler's academic research focused on human genetic variation and its application to disease, using information from the Human Genome Project. He has co-led the SNP Consortium, International HapMap Project, and 1000 Genomes Project His research focused on the genetic basis of Type 2 Diabetes, and his laboratory contributed to mapping dozens of gene variants that are associated with risk of Type 2 Diabetes, lipid levels, myocardial infarction, rheumatoid arthritis, lupus, prostate cancer, and other disorders.